Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.
Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsch A. Colleoni M, et al. Among authors: zorzino l. Ann Oncol. 2002 Jan;13(1):73-80. doi: 10.1093/annonc/mdf013. Ann Oncol. 2002. PMID: 11863115 Free article. Clinical Trial.
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.
Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nolè F, Viale G, Goldhirsch A. Colleoni M, et al. Among authors: zorzino l. Ann Oncol. 2006 Feb;17(2):232-8. doi: 10.1093/annonc/mdj066. Epub 2005 Dec 1. Ann Oncol. 2006. PMID: 16322118 Free article. Clinical Trial.
Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
Curigliano G, De Braud F, Teresa Sandri M, Renne G, Zorzino L, Scardino E, Rocco B, Spitaleri G, De Pas T, Noberasco C, Nolè F, Verweij F, Matei V, De Cobelli O. Curigliano G, et al. Among authors: zorzino l. Anticancer Drugs. 2007 Sep;18(8):949-54. doi: 10.1097/CAD.0b013e328136c162. Anticancer Drugs. 2007. PMID: 17667601 Clinical Trial.
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
Zampino MG, Magni E, Santoro L, Zorzino L, Dell'Orto P, Sonzogni A, Fazio N, Monfardini L, Chiappa A, Biffi R, de Braud F. Zampino MG, et al. Among authors: zorzino l. Cancer Chemother Pharmacol. 2008 Dec;63(1):139-48. doi: 10.1007/s00280-008-0722-x. Epub 2008 Mar 8. Cancer Chemother Pharmacol. 2008. PMID: 18327586 Clinical Trial.
Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer.
Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, Salvatici M, Verri E, Adamoli L, Goldhirsch A, Nolè F. Botteri E, et al. Among authors: zorzino l. Breast Cancer Res Treat. 2010 Jul;122(1):211-7. doi: 10.1007/s10549-009-0668-7. Epub 2009 Dec 6. Breast Cancer Res Treat. 2010. PMID: 19967556
Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents.
Noberasco C, Spitaleri G, Mancuso P, Zorzino L, Radice D, Milani A, Rocca A, Bertolini F, Sandri MT, Curigliano G, de Pas T, Jemos C, Omodeo Salè E, Boselli S, de Braud F. Noberasco C, et al. Among authors: zorzino l. Oncology. 2009;77(6):358-65. doi: 10.1159/000275830. Epub 2010 Jan 11. Oncology. 2009. PMID: 20068365 Clinical Trial.
49 results